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Effect  of  HLA-­DRB1  alleles  and  genetic  variants  on  the  development  of  
neutralizing  antibodies   to   interferon  beta   in   the  BEYOND  and  BENEFIT  
trials  
Abstract  
Background:  Treatment  of  multiple  sclerosis  with  interferon  β  can  lead  to  the  
development  of  antibodies  directed  against  interferon  β  that  interfere  with  
treatment  efficacy.  Several  observational  studies  have  proposed  different  HLA  
alleles  and  genetic  variants  associated  with  the  development  of  antibodies  
against  interferon  β.  
Objective:  To  validate  the  proposed  genetic  markers  and  to  identify  new  
markers.  
Methods:  Associations  of  genetic  candidate  markers  with  antibody  presence  
and  development  were  examined  in  a  post  hoc  analysis  in  941  patients  
treated  with  interferon  β-­1b  in  the  BEYOND  and  BENEFIT  prospective  phase  
III  trials.  All  patients  were  treated  with  interferon  β-­1b  for  at  least  six  months.  
In  addition,  a  genome-­wide  association  study  was  conducted  to  identify  new  
genetic  variants.  
Results:  We  confirmed  an  increased  risk  for  carriers  of  HLA-­DRB1*04:01  
(OR=3.3,  p=6.9×10-­4)  and  HLA-­DRB1*07:01  (OR=1.8,  p=3.5×10-­3)  for  
developing  neutralizing  antibodies  (NAbs).  Several  additional,  previously  
proposed  HLA  alleles  and  genetic  variants  showed  nominally  significant  
associations.  In  the  exploratory  analysis,  variants  in  the  HLA  region  were  




Conclusion:  The  contribution  of  HLA  alleles  and  HLA-­associated  SNPs  to  the  
development  and  titer  of  antibodies  against  interferon  β  was  confirmed  in  the  
combined  analysis  of  two  multi-­national,  multi-­center  studies.  
  
Introduction  
Biopharmaceuticals  provide  new  opportunities  for  treatment  of  severe  
diseases.  In  a  subset  of  patients,  however,  these  protein-­based  drugs  induce  
an  unintended  immune  response  against  the  biopharmaceutical1-­3.  The  
development  of  antibodies  against  biopharmaceutical  drugs  (anti-­drug  
antibodies,  ADA)  may  thus  be  a  major  limitation  of  treatment  efficacy4,5.  
Interferon  β-­preparations  are  widely  used  to  treat  multiple  sclerosis  (MS)  or  
clinically  isolated  syndrome  (CIS).  Overall,  up  to  40%  of  patients  will  
eventually  develop  antibodies  against  interferon  β6-­9,  of  which  a  significant  
proportion  neutralize  the  biological  activity  of  interferon  β    (neutralizing  
antibodies,  NAbs)10,11.  Several  factors  related  to  either  the  interferon  β  
compound  and  administration  or  the  individual  patient  influence  
immunogenicity6,12-­14.    
In  two  previous  studies  on  German  MS  patients,  HLA  class  II  alleles  were  
found  to  influence  the  development  of  ADA  against  interferon  β.  HLA-­
DRB1*04:01  and  HLA-­DRB1*04:08  showed  significant,  HLA-­DRB1*03:01,  
HLA-­DRB1*04:04,  HLA-­DRB1*11:01,  HLA-­DRB1*11:04,  and  HLA-­
DRB1*16:01  nominal  associations  with  ADA  titer15,16.  In  addition,  an  
association  of  HLA-­DRB1*07:01  with  ADAs  was  described  for  39  American  
patients17.  A  study  conducted  on  610  Spanish  patients  reported  an  increased  
risk  of  developing  NAbs  for  the  combined  presence  of  the  haplotype  HLA-­
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DRB1*07:01  with  the  HLA  class  I  alleles  HLA-­A*26  and  HLA-­B*14  and  
replicated  the  association  of  DRB1*04:0118.  In  a  Swedish  analysis,  the  HLA-­
DRB1*15  and  HLA-­DQA1*05  alleles  were  associated  with  an  increased  risk  
for  developing  NAbs  in  patients  treated  with  interferon  β-­1a19,  while  HLA-­
DRB1*04  was  nominally  associated  in  patients  receiving  interferon  β-­1b.  In  a  
genome-­wide  association  study  (GWAS)  on  German  patients,  two  single  
nucleotide  polymorphisms  (SNPs),  rs9272105  (linked  to  the  HLA  class  II  
locus)  and  rs4961252  (linked  to  an  intergenic  region  on  chromosome  8),  were  
significantly  associated  with  ADA  titers20.    
The  aim  of  the  current  study  was  to  validate  these  genetic  markers  in  the  
setting  of  two  multi-­national  phase  III  trials  conducted  on  patients  treated  with  




Patients  were  treated  with  interferon  β-­1b  in  two  phase  III  trials.  These  studies  
were  the  BEtaseron®/BEtaferon®  in  Newly  Emerging  multiple  sclerosis  For  
Initial  Treatment  trial  (BENEFIT;;  clinicaltrials.gov  ID:  NCT00185211)21  and  the  
Betaferon®  Efficacy  Yielding  Outcomes  of  a  New  Dose  trial  (BEYOND;;  
clinicaltrials.gov  ID:  NCT00099502)22.  In  BENEFIT,  478  CIS  patients  were  
randomized  to  interferon  β-­1b  250  μg,  administered  subcutaneously  every  
other  day,  or  placebo  (5:3  ratio).  Patients  received  placebo  for  two  years  or  
until  MS  was  diagnosed  using  the  Poser  criteria23.  Patients  were  then  offered  
interferon-­β-­1b  for  up  to  five  years.  In  BEYOND,  2244  patients  with  relapsing-­
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remitting  MS  (RRMS)  were  randomized  in  a  2:2:1  ratio  to  receive  either  
interferon  β-­1b  500  μg,  interferon  β-­1b  250  μg,  both  administered  
subcutaneously  every  other  day,  or  glatiramer  acetate  20  mg,  administered  
subcutaneously  daily  for  a  period  of  2  or  up  to  3.5  years.  Details  of  the  study  
protocols  and  results  of  NAb  testing  were  published  elsewhere22,24-­26.  
In  the  analyses  presented  in  this  manuscript,  we  included  patients  who  had  
given  informed  consent  for  genetic  testing  and  who  were  treated  with  
interferon  β-­1b  for  at  least  six  months  with  a  dose  of  either  250  µg  (n=567)  or  
500  µg  (n=374).  This  dose  was  included  as  a  covariate  in  the  analyses.  
Because  ADA  development  usually  occurs  within  the  first  year  of  treatment27,  
genetic  association  analyses  were  restricted  to  patients  who  had  either  
received  interferon  β-­1b  for  at  least  six  months  and  showed  a  positive  NAb  
result  or  who  had  continuously  received  interferon  β-­1b  for  at  least  twelve  
months,  irrespective  of  NAb  status.  Patients  with  missing  information  in  
clinical  covariates  as  well  as  genetic  outliers  were  excluded,  leading  to  a  final  
number  of  941  patients  included  in  the  analyses  after  quality  control  (QC).  
Measurement  of  antibodies  against  interferon  β  
In  both  clinical  trials,  serum  samples  were  collected  at  baseline  and  every  six  
months  after  that  to  evaluate  anti-­interferon  β-­1b  antibodies  using  the  
Myxovirus  protein  A  (MxA)  induction  assay28.  Measurement  of  anti-­interferon  
β-­1b  antibodies  was  conducted  in  the  same  laboratory  for  both  clinical  trials  
(Rentschler  Biotechnologie  GmbH,  Laupheim,  Germany).  A  titer  of  20  
normalized  units  (NU)/mL  was  used  as  a  cut-­off  between  NAb  negativity  and  
positivity.  Patients  without  a  NAb-­positive  sample  and  with  either  a  treatment  
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interruption  of  more  than  90  days  in  the  first  treatment  year  or  with  a  missing  
NAb  measurement  at  year  one  and  later  were  excluded  from  analyses.  
Study  Endpoints  
The  predefined  primary  endpoint  (EP)  was  the  presence  of  NAbs  at  any  time  
during  the  studies  (EP1).  This  endpoint  was  analyzed  in  all  eligible  patients.  
Secondary  endpoints  were  mean  NAb  titer  (EP2),  the  area  under  the  NAb  
curve  (NAb  AUC)  of  four  measurements  performed  during  the  first  two  
treatment  years  (EP3),  the  maximum  NAb  titer  during  the  first  two  years  
(EP4),  and  time  to  first  NAb  presence  (EP5).  EP5  was  assessed  in  NAb-­
positive  patients  only.  Because  the  duration  of  the  BENEFIT  trial  was  longer  
than  the  BEYOND  trial,  EP3  and  EP4  potentially  differed  systematically  
between  the  studies.  To  prevent  bias  in  these  endpoints,  EP3  and  EP4  were  
only  assessed  during  the  first  two  years  of  either  study.  In  addition  to  the  
examination  of  candidate  variants,  a  hypothesis-­free  GWAS  was  conducted  
for  each  endpoint  as  an  explorative  analysis.  
Sequencing,  genotyping,  and  imputation  
HLA-­DRB1  alleles  were  sequenced  by  LGC-­Genomics  (formerly  AGOWA)  
using  the  HLA-­DRB1  AlleleSEQR/HARP  kits  from  Abbott  Molecular.  
Genotyping  was  conducted  using  the  Affymetrix  Genome-­Wide  Human  SNP  
Array  6.0.  QC  steps  on  samples  included  removal  of  individuals  with  a  
genotyping  rate  <98%  and  of  genetic  outliers  using  EIGENSTRAT29  (for  
details  see  Supplementary  Table  e-­1).  926  of  the  941  remaining  samples  
were  of  Caucasian  ancestry  (Supplementary  Table  e-­2  and  Supplementary  
Figure  e-­1).  QC  steps  on  variants  included  removal  of  variants  with  a  call  rate  
<98%,  a  MAF  <1%,  or  a  Hardy-­Weinberg  equilibrium  test  p-­value  <10-­6.  
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Imputation  of  genotype  data  was  conducted  to  the  1000  Genomes  Phase  3  
reference  panel  in  5  Mbp  chunks  using  SHAPEIT  v2.r837  for  phasing  and  
IMPUTE2  v2.3.2  for  imputation30-­32.  Imputed  variants  were  filtered  for  MAF  
(≥1%)  and  INFO  metric  (≥0.8).  The  final  dataset  contained  8,671,751  variants  
and  941  patients.  
Statistical  Analyses  
For  EP1,  the  presence  of  NAbs,  logistic  regression  was  used.  Endpoints  EP2-­
EP4  were  analyzed  using  linear  regression.  A  Cox  proportional  hazards  
model  was  used  to  analyze  EP5  using  the  R  package  survival33.  Endpoints  
EP2-­EP4  were  inverse-­normally  transformed  to  normal  distributions  before  
analysis.  The  following  covariates  were  used  in  all  analyses:  Study  (BENEFIT  
/  BEYOND),  sex,  age,  interferon  β-­1b  treatment  dose  (250  μg  /  500  μg),  
interferon  β-­1b  treatment  duration,  and  the  first  six  multidimensional  scaling  
(MDS)  components  of  the  genetic  similarity  matrix  to  control  for  population  
substructure  (Supplementary  Figure  e-­1).  For  EP5,  the  study  was  included  as  
a  stratification  variable  to  meet  the  proportional  hazards  assumption.  Test  
statistics  were  not  inflated  in  any  model  (genomic  inflation  λ  ≤  1.025).  For  the  
analysis  of  candidate  variants,  the  significance  threshold  α  was  Bonferroni-­
corrected  for  eleven  tests  (α=0.0045).  Because  HLA-­DRB1*15  and  HLA-­
DRB1*15:01  are  not  independent  of  each  other,  they  were  not  considered  as  
separate  alleles  for  calculation  of  this  significance  threshold.  All  analyses  of  
candidate  variants  were  conducted  in  R  v3.2.1.  The  GWAS  was  conducted  in  
PLINK2  v1.90b3.38  for  EP1-­EP434,  and  in  R  for  EP5.  The  significance  
threshold  for  the  GWAS  was  α=5×10-­8.  In  addition  to  the  analyses  in  the  
complete  set  of  patients,  EP2-­EP5  were  analyzed  separately  using  the  same  
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methods  and  covariates  within  the  subgroup  of  NAb-­positive  patients.  The  
eQTL  data  was  obtained  from  the  Genotype-­Tissue  Expression  (GTEx)  





A  total  of  941  patients  from  the  BENEFIT  and  BEYOND  trials  were  analyzed  
in  this  study.  Of  these,  361  patients  developed  NAbs  during  the  trials  (Table  
1).  All  941  patients  had  genotyping  data  available,  while  HLA  sequencing  was  
available  for  only  678  of  them.  Eleven  genetic  markers,  at  least  nominally  
associated  with  ADA  in  previous  studies,  were  selected  as  candidates:  HLA-­
DRB1*04:01  and  HLA-­DRB1*04:08,  significantly  associated  with  ADA  titers  in  
two  previous  publications15,16,  as  well  as  HLA-­DRB1*03:01,  HLA-­DRB1*04:04,  
HLA-­DRB1*11:01,  HLA-­DRB1*11:04,  and  HLA-­DRB1*16:01,  nominally  
associated  in  either  of  these  studies.  Markers  selected  from  additional  studies  
were  the  haplotype  HLA-­DRB1*15,  associated  with  NAb  development19,  HLA-­
DRB1*07:01,  associated  with  ADAs17,  and  two  SNPs,  rs9272105  and  
rs4961252,  associated  with  ADA  titers20.  
Candidate  genetic  markers  associated  with  the  presence  of  NAbs  
Patients  with  a  NAb  titer  of  ≥  20  NU/mL  in  any  measurement  were  defined  as  
NAb-­positive.  Considering  NAb-­positive  patients  as  cases  and  NAb-­negative  
ones  as  controls,  we  conducted  a  logistic  regression  on  NAb  presence.  Of  the  
candidate  markers,  HLA-­DRB1*04:01  and  HLA-­DRB1*07:01  were  significantly  
associated  with  the  presence  of  NAbs  after  correction  for  multiple  testing  
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(eleven  tests,  α=0.0045,  Table  2).  In  addition,  HLA-­DRB1*11:01  and  the  HLA-­
associated  SNP  rs9272105  were  nominally  associated  (one-­sided  p-­values)  
and  all  candidate  markers  except  for  rs4961252,  HLA-­DRB1*15,  and  HLA-­
DRB1*15:01  showed  the  direction  of  effect  expected  from  the  previous  
publications  (Table  2).  
Association  of  candidate  genetic  markers  with  secondary  endpoints    
We  performed  analyses  for  the  three  secondary  endpoints  mean  NAb  titer  
(EP2),  NAb  AUC  (EP3),  and  maximum  NAb  titer  (EP4)  using  linear  regression  
on  all  patients.  These  three  measurements  were  highly  correlated  
(Spearman's  correlation  coefficients  ≥  0.98,  Supplementary  Table  e-­3).  
Accordingly,  results  for  EP2  (Table  3)  were  highly  similar  to  EP3  and  EP4  
(Supplementary  Tables  e-­5  and  e-­6),  with  quantitative  differences  in  p-­values.  
Qualitatively,  these  results  were  also  very  similar  to  the  analysis  of  EP1  
(Table  2).  In  addition  to  the  variants  already  nominally  or  significantly  
associated  with  EP1,  HLA-­DRB1*04:08  was  nominally  associated  with  EP2  
(Table  3).  
Association  of  candidate  genetic  markers  in  NAb-­positive  patients  
Similar  to  our  primary  endpoint  and  previous  studies,  the  analysis  of  EP2-­EP4  
in  all  patients  addressed  the  question  whether  candidate  markers  influence  
the  risk  of  developing  NAbs.  However,  genetic  variants  might  also  influence  
the  titer  of  NAbs  once  a  patient  has  already  developed  ADA.  To  examine  this  
hypothesis,  we  repeated  analyses  in  the  subset  of  patients  that  developed  
NAbs  within  the  first  two  years,  excluding  NAb-­negative  patients.  The  sample  
size  for  this  analysis  was  only  approximately  one-­third  of  the  complete  
number  of  available  patients  (Supplementary  Table  e-­4).  In  this  subset  of  
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patients,  HLA-­DRB1*04:08,  HLA-­DRB1*07:01,  and  variant  rs9272105  were  
nominally  associated  with  mean  NAb  titer,  but  no  variant  remained  associated  
after  correcting  for  multiple  testing  (Supplementary  Tables  e-­7  to  e-­9).  
EP5,  time  to  NAb  presence,  was  only  analyzed  in  NAb-­positive  patients,  using  
a  Cox  proportional  hazard  model.  Under  the  hypothesis  that  risk  alleles  
should  decrease  the  time  to  the  presence  of  NAbs,  markers  rs9272105  and  
HLA-­DRB1*15  were  nominally  associated,  yet  no  association  of  candidate  
markers  remained  significant  after  correction  for  multiple  testing  
(Supplementary  Table  e-­10).  
Explorative  GWAS  for  all  endpoints  
The  main  objective  of  our  study  was  the  replication  of  candidate  variants  from  
previous  publications.  However,  as  we  had  genome-­wide  genotyping  data  
available  for  all  patients,  we  also  conducted  exploratory  GWAS  to  identify  
novel  variants  associated  with  the  development  of  ADA.  For  EP1,  the  SNP  
showing  the  overall  highest  association  was  rs522308  (OR  2.60  (CI  2.05-­
3.29),  p=2.30×10-­15),  located  in  between  HLA-­DRB1  and  HLA-­DQA1  (Figure  
1A,  Supplementary  Figure  e-­2,  Supplementary  Table  e-­11).  Variant  rs522308  
was  in  weak  linkage  disequilibrium  (LD)  with  the  candidate  SNP  rs9272105  
(r2=0.15)  and  with  HLA  allele  HLA-­DRB1*07:01  (r2=0.28).  In  the  GWAS  for  
EP2-­4,  the  SNP  rs2454138  showed  the  overall  highest  association  (EP2:  
β=0.41±0.05,  p=5.29×10-­19;;  Figure  1B,  Supplementary  Figures  e-­3  to  e-­5,  
Supplementary  Table  e-­11).  This  variant  is  in  strong  LD  with  the  upstream  
EP1-­associated  SNP  rs522308  (r2=0.88).  Test  statistics  were  not  inflated:  the  
median  genomic  inflation  factor  λ  ranged  from  1.014  to  1.025  for  the  different  
endpoints.  Variant  rs522308  is  significantly  associated  with  expression  of  
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several  HLA  class  II  genes  in  whole  blood  in  the  public  expression  
quantitative  trait  locus  (eQTL)  database  GTEx  (Supplementary  Table  e-­12)35.  
Neither  rs2454138  nor  rs9272105  was  part  of  any  eQTL  in  this  database.  
Finally,  we  also  conducted  GWAS  on  all  endpoints  in  NAb-­positive  patients  
only.  However,  no  variant  reached  genome-­wide  significance  here  
(Supplementary  Figures  e-­6  to  e-­9).  
  
Discussion  
Interferon  β  is  a  well-­established  first-­line  treatment  in  MS.  Up  to  40%  of  
patients  treated  with  interferon  β  develop  ADA,  most  of  them  with  neutralizing  
activity,  that  may  antagonize  the  therapeutic  activity  of  the  drug6.  Although  the  
immunogenicity  of  biopharmaceuticals  is  a  known  critical  phenomenon,  
reasons  for  the  large  inter-­individual  variation  in  the  occurrence  of  ADA  are  
still  poorly  understood.  In  previous  studies,  nine  HLA-­DRB1  alleles  and  two  
SNPs  have  been  proposed  to  either  influence  the  risk  to  develop  anti-­
interferon  β  antibodies  or  to  be  associated  with  ADA  titers15-­20.  Six  of  these  
markers  are  assumed  to  increase  the  risk  for  ADA  development,  the  
remaining  five  are  candidates  for  protection  from  ADA.  
In  the  current  study,  these  genetic  markers  were  evaluated  in  an  independent  
dataset  of  patients  with  CIS  or  RRMS  from  two  large  international  phase  III  
clinical  trials,  carefully  monitored  for  ADA  titer  and  persistence  of  ADA  over  
time.  We  confirmed  the  associations  of  HLA-­DRB1*04:01  and  HLA-­
DRB1*07:01  with  NAb  presence  (Table  2)  and  NAb  titer  (Table  3).  Seven  of  
the  remaining  candidate  markers  showed  an  association  following  the  
published  direction  of  the  effect  but  were  not  significant  after  correction  for  
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multiple  testing.  For  some  of  the  candidate  alleles,  the  power  in  our  study  was  
very  low  due  to  their  low  frequencies  (e.g.,  previously  proposed  HLA-­
DRB1*04:08  was  present  in  only  2.1%  of  patients).  Non-­significant  
associations  in  the  expected  directions  thus  do  not  imply  that  these  alleles  are  
not  associated  with  NAb  presence.  Analyses  of  the  secondary  EPs  showed  
very  similar  results  (Table  3,  Supplementary  Tables  e-­5  and  e-­6).  Overall,  
quantitative  mean  NAb  titer  (EP2)  was  more  strongly  associated  with  
candidate  variants  than  binary  NAb  presence  (EP1).  This  increased  sensitivity  
indicates  that  the  pre-­defined  threshold  for  NAb  positivity  (20  NU/mL)  was  not  
optimally  chosen.  Indeed,  these  results  suggest  that  for  future  genetic  
association  studies,  mean  antibody  titers  might  be  better  suited  than  NAb  
presence  defined  by  a  fixed  cut-­off.  
Discordant  results  with  and  among  published  associations  likely  arose  from  
different  allele  frequencies  in  the  investigated  populations,  different  
distributions  of  interferon  β  preparations  in  the  study  cohorts,  and  different  
assays  for  ADA  measurement.  In  general,  the  heterogeneous  geographical  
and  thus  genetic  background  of  BENEFIT  and  BEYOND  patients  likely  led  to  
a  decrease  in  power  in  our  analysis  (Supplementary  Figure  e-­1).  Another  
reason  for  observed  discrepancies  might  lie  in  the  assay  used.  In  our  current  
study,  NAb  titers  were  measured  through  an  MxA  induction  in  vitro  assay.  In  a  
previous  Swedish  study,  an  MxA  protein  assay,  as  well  as  an  MxA  gene  
expression  assay,  were  used19.  In  previous  German  publications,  
identification  of  genetic  risk  alleles  was  based  on  ADA  titers  determined  by  
capture  ELISA  and  NAbs  assessed  by  in  vivo  MxA  measurements15,16,20.  
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In  the  study  on  Swedish  patients,  the  HLA-­DRB1*15  allele  was  associated  
with  NAb  development  in  interferon  β  1a-­treated  patients19.  However,  in  two  
previous  studies  on  German  patients,  not  stratified  for  interferon  β  
preparations15,16,  as  well  as  in  our  current  analysis,  restricted  to  interferon  β-­
1b,  HLA-­DRB1*15  was  not  more  common  among  patients  developing  ADA  
(Table  2).  Of  note,  Link  et  al.  had  examined  the  haplotype  HLA-­DRB1*15  
only19.  In  addition,  we  also  included  the  most  frequent  HLA-­DRB1*15  allele  
HLA-­DRB1*15:01  in  our  analyses,  which  was  weakly  correlated  with  the  
candidate  SNP  rs9272105  (r2=0.30).  Like  HLA-­DRB1*15,  HLA-­DRB1*15:01  
was  neither  more  common  among  patients  with  NAbs  nor  associated  with  
increased  NAb  titers  (Tables  2  and  3).  Interestingly,  both  HLA-­DRB1*15  and  
rs9272105  were  associated  at  nominal  significance  with  time  to  maximum  
NAb  titer  (EP5,  Supplementary  Table  e-­10).  
In  a  previously  published  German  cohort,  the  minor  allele  G  of  the  imputed  
SNP  rs4961252  was  associated  with  higher  ADA  titers20.  However,  in  our  
international  cohort,  the  SNP  was  negatively  associated  with  NAbs.  The  most  
likely  explanation  for  this  phenomenon  is  a  flip-­flop  effect36.  Such  an  effect  
can  occur  if  a  tested  candidate  marker  is  a  non-­causal  common  variant  in  
weak  LD  with  the  unknown  real  causal  variant.  Under  these  circumstances,  
the  effect  direction  of  the  candidate  variant  can  reverse  due  to  sampling  
variation,  especially  when  examining  multi-­ethnic  populations.  This  means  
that  rs4961252  is  likely  not  the  causal  variant,  but  that  it  is  in  weak  LD  with  the  
actual  causal  SNP,  which  remains  to  be  identified.    
In  addition  to  analyses  on  the  complete  set  of  patients,  we  also  examined  the  
subset  of  NAb-­positive  patients.  The  significant  association  of  HLA-­
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DRB1*04:01  in  all  patients  was  not  supported  in  analyses  of  NAb-­positive  
patients  (Supplementary  Tables  e-­7  to  e-­10).  By  contrast,  the  allele  HLA-­
DRB1*04:08  showed  the  strongest  nominal  association  with  EP2-­4  in  NAb-­
positive  patients.  It  is,  therefore,  possible  that  HLA-­DRB1*04:01  is  important  
for  the  risk  to  develop  NAbs  and  that  HLA-­DRB1*04:08  is  relevant  for  an  
increased  NAb  titer.    
  
Conclusion  
In  summary,  our  study  confirms  a  genetic  association  of  the  HLA  class  II  locus  
with  the  development  of  ADA  against  interferon  β-­1b.  This  association  was  
confirmed  in  both  analyses  of  candidate  variants  and,  indirectly,  in  hypothesis-­
free  GWAS.  Our  validation  of  the  importance  of  the  HLA  class  II  locus  fits  well  
into  the  pathophysiologic  concept  because  HLA  class  II  proteins  are  crucial  
for  antigen  presentation  to  CD4+  T  cells  that  are  necessary  for  inducing  the  B  
cell  response  and  subsequent  antibody  production.  In  future  studies,  a  larger  
dataset  needs  to  be  examined,  including  several  subsets  of  in  each  case  
genetically  homogeneous  samples  selected  from  different  populations  and  
different  interferon  β  preparations.  Importantly,  all  patients  will  need  to  be  
evaluated  using  the  same  assay,  ideally  both  for  ADA  and  for  NAbs.  These  
studies  will  help  to  elucidate  the  contribution  of  genetic  variations  to  ADA  
development  further.  The  ultimate  aim  of  such  analyses  should  be  the  
establishment  of  prediction  algorithms  for  ADA  development.  
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Table  1:  Characteristics  of  BEYOND  and  BENEFIT  patients  included  in  the  
analyses.  Only  a  subset  of  patients  had  HLA  data  available.  For  all  median  
values,  the  median  absolute  deviation  is  indicated  in  brackets.  Additional  
characteristics  of  these  patients  as  well  as  characteristics  for  the  subset  of  
patients  that  developed  NAbs  within  the  first  two  years  are  shown  in  
Supplementary  Tables  e-­3  and  e-­4,  respectively.  
Measurement   With  SNP  data   With  HLA  data  
Number  of  samples   941   678  
Study:  BEYOND  (n  (%))   766  (81.4)   669  (98.7)  
Sex:  Female  (n  (%))   661  (70.2)  
472  (69.6)  
Median  age  (years)   35  (10.4)   36  (10.4)  
Median  disease  duration  (years)   2.3  (3.5)   3.3  (3.9)  
Median  EDSS   2  (1.5)   2  (0.7)  
Median  cumulative  newly  active  lesions  during  the  studies   1  (1.5)   1  (1.5)  
Interferon  β-­1b  dose:  250  μg  (n  (%))   567  (60.3)  
352  (51.9)  
Median  duration  of  treatment  (years)   2.6  (0.6)   2.6  (0.5)  
Minimum  duration  of  treatment  with  interferon  β-­1b  (years)   0.5   1.5  
Median  total  dose  of  interferon  β-­1b  (mg)   182.5  (81)   151.8  (71.9)  
Presence  of  NAbs  at  least  during  one  measurement  (%),  EP1   361  (38.4)  
252  (37.2)  
Median  mean  NAb  titer  (NU/ml),  EP2  (including  NAb-­negative  
patients)  




Table  2:  Summary  statistics  for  the  association  analysis  of  the  presence  of  
NAbs  (NAb  titer  ≥  20  NU/mL)  with  candidate  markers  (logistic  regression).  
The  Bonferroni-­corrected  significance  threshold  was  α=4.5×10-­3  (eleven  tests,  
because  the  tests  for  HLA-­DRB1*15  and  for  HLA-­DRB1*15:01  were  not  
independent  of  each  other).  Chr  =  chromosome,  Freq  =  frequency,  n  =  
sample  size,  OR  =  odds  ratio,  CI  =  95  %  confidence  interval,  p-­value  (1-­sided)  
=  one-­sided  p-­value  for  replication  based  on  the  direction  of  effect  expected  
from  the  literature  (the  published  effect).  Alleles  significant  after  multiple  
testing  are  labeled  in  bold  font,  nominally  significant  results  in  italics.  




n   OR  (CI)   Published  
effect  
p-­value   p-­value  
(1-­sided)  
6   HLA-­DRB1   *04:01   11.9   678   3.33  (1.66-­6.67)   >1   6.9×10-­04   3.5×10-­04  
6   HLA-­DRB1   *04:08   2.1   678   2.15  (0.42-­10.95)   >1   3.6×10-­01   1.8×10-­01  
6   HLA-­DRB1   *07:01   9.5   678   1.78  (1.21-­2.61)   >1   3.5×10-­03   1.7×10-­03  
6   HLA-­DRB1   *15   25.5   678   0.73  (0.56-­0.96)   >1   2.6×10-­02   9.9×10-­01  
6   HLA-­DRB1   *15:01   24.0   678   0.75  (0.57-­0.99)   >1   4.2×10-­02   9.8×10-­01  
6   HLA-­DRB1   *16:01   2.6   678   1.62  (0.6-­4.37)   >1   3.4×10-­01   1.7×10-­01  
6   HLA-­DRB1   *03:01   2.9   678   0.87  (0.61-­1.23)   <1   4.2×10-­01   2.1×10-­01  
6   HLA-­DRB1   *04:04   0.4   678   0.58  (0.25-­1.34)   <1   2.0×10-­01   1.0×10-­01  
6   HLA-­DRB1   *11:01   1.2   678   0.64  (0.4-­1.02)   <1   6.3×10-­02   3.1×10-­02  
6   HLA-­DRB1   *11:04   6.9   678   0.66  (0.32-­1.38)   <1   2.7×10-­01   1.3×10-­01  
8   intergenic   rs4961252_G   40.6   941   0.92  (0.74-­1.14)   >1   4.5×10-­01   7.7×10-­01  




Table  3:  Summary  statistics  for  the  association  analysis  of  mean  NAb  titer  
with  candidate  markers  (linear  regression).  Significance  thresholds  and  
abbreviations  are  as  described  in  the  legend  of  Table  2.  SE  =  standard  error  
(shown  instead  of  CI  because  of  the  quantitative  phenotype).  




n   Effect   SE   Published  
effect  
p-­value   p-­value  
(1-­sided)  
6   HLA-­DRB1   *04:01   11.9   678   0.39   0.13   >0   1.8×10-­03   8.9×10-­04  
6   HLA-­DRB1   *04:08   2.1   678   0.75   0.33   >0   2.1×10-­02   1.1×10-­02  
6   HLA-­DRB1   *07:01   9.5   678   0.25   0.07   >0   9.1×10-­04   4.6×10-­04  
6   HLA-­DRB1   *15   25.5   678   -­0.12   0.05   >0   1.8×10-­02   9.9×10-­01  
6   HLA-­DRB1   *15:01   24.0   678   -­0.12   0.05   >0   1.6×10-­02   9.9×10-­01  
6   HLA-­DRB1   *16:01   2.6   678   0.22   0.19   >0   2.5×10-­01   1.2×10-­01  
6   HLA-­DRB1   *03:01   2.9   678   -­0.08   0.06   <0   2.1×10-­01   1.0×10-­01  
6   HLA-­DRB1   *04:04   0.4   678   -­0.11   0.15   <0   4.7×10-­01   2.3×10-­01  
6   HLA-­DRB1   *11:01   1.2   678   -­0.18   0.08   <0   3.5×10-­02   1.7×10-­02  
6   HLA-­DRB1   *11:04   6.9   678   -­0.20   0.13   <0   1.1×10-­01   5.7×10-­02  
8   intergenic   rs4961252_G   40.6   941   -­0.07   0.04   >0   1.0×10-­01   9.5×10-­01  





Figure  1:  Regional  association  plots  for  lead  variants  identified  in  the  GWAS  
(see  Supplementary  Table  e-­11).  The  red  line  marks  the  genome-­wide  
significance  level  (5×10-­8).  Color  of  dots  indicates  LD  with  the  lead  variant  
(pink);;  note  that  all  variants  showing  genome-­wide  significance  were  in  LD  
with  the  respective  lead  variants.  Gray  dots  represent  signals  with  missing  R2  
values.  The  bottom  box  indicates  the  positions  of  HLA  genes.  Mbp  =  Mega  
base  pairs.  A:  GWAS  of  EP1  in  all  patients,  showing  the  strength  of  evidence  
for  association  with  NAb  presence  (rs522308  p=2.30×10-­15,  genomic  inflation  
λ  =  1.025).  B:  GWAS  of  EP2  in  all  patients,  showing  the  strength  of  evidence  
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Supplementary Table e-1: Quality control (QC) of genotyping data. QC of genotyped data 
was conducted in two separate iterations. The first QC took place following genotyping using 
PLINK, a second, refined round of QC before imputation using PLINK2 v1.90b3s. QC of 
imputed probabilities was conducted in QCTOOL v1.4 
(http://www.well.ox.ac.uk/~gav/qctool/). 
Samples were removed according to 
the following criteria: 
Variants were removed according to the 
following criteria: 
Individual genotyping rate < 98 % Variant call rate < 98 % 
Gender mismatches  Minor allele frequency < 1 % 
Cryptic relatedness (PI-HAT) > 0.05 HWE test p-value (first round) < 10-6 
Removal of genetic outlier via 
EIGENSTRAT/SMARTPCA 
> 6 SD HWE test p-value (second round, 
after removal of individuals) 
< 10-7 
Significant deviation of autosomal 
heterozygosity from the mean 
Variants on non-autosomal 
chromosomes 
 
 Ambivalent SNPs (A/T and G/C) 
Variants not present in the 1000 
Genomes Phase 3 reference panel 
IMPUTE2 info metric < 0.8 
 
Supplementary Table e-2: Ethnicities of samples. Based on genotype data, samples of non-
Caucasian ancestry clustered together with samples of Caucasian ancestry (Supplementary 
Figure e-1). 








Supplementary Table e-3: Additional characteristics of BEYOND and BENEFIT patients 
included in the analyses. For all median values, the median absolute deviation is indicated in 
brackets.  
Measurement With SNP data With HLA data 
Median NAb AUC during the first two years (Years*NU/mL), 
EP3  (including  NAb-­negative  patients) 
0 (0) 0 (0) 
Median maximum NAb titer during the first two years (NU/ml), 
EP4  (including  NAb-­negative  patients) 
0 (0) 0 (0) 
Minimal maximum NAb titer in any individual (NU/ml),  
including  NAb-­negative  patients 
0 0 
Median time to the presence of a positive NAb titer, if NAbs 
were developed (months), EP5 
6 (0) 6 (0) 
Spearman correlation of mean NAb titer to NAb positivity 0.949 0.952 
Spearman correlation of mean NAb titer to NAb AUC 0.997 0.999 
Spearman correlation of mean NAb titer to max. NAb titer 0.998 0.999 






Supplementary Table e-4: Characteristics of NAb-positive patients having developed NAb 
within two years (secondary analysis set). NAb-positive patients were defined as having a 
titer >20 NU/mL during the first two years of either study. Only a subset of patients had HLA 
data available. For all median values, the median absolute deviation is indicated in brackets. 
Measurement With SNP data With HLA data 
Number of samples 353 247 
Study: BEYOND (n (%)) 289 (81.9) 246 (99.6) 
Sex: Female (n (%)) 246 (69.7) 168 (68.0) 
Median age (years) 38 (10.4) 39 (10.4) 
Median disease duration (years) 2.5 (3.7) 3.4 (4) 
Median EDSS 2 (1.5) 2 (1.5) 
Median cumulative newly active lesions during the studies 2 (3) 2 (3) 
Interferon β-1b dose: 250 μg (n (%)) 202 (57.2) 121 (49.0) 
Median duration of treatment (years) 2.7 (0.6) 2.6 (0.5) 
Minimum duration of treatment with interferon β-1b (years) 0.5 1.5 
Median total dose of interferon β-1b (mg) 187.2 (84.5) 184.2 (90.1) 
Presence of NAbs (n (%)), EP1 353 (100) 247 (100) 
Median mean NAb titer (NU/ml), EP2 55 (69.7) 58.5 (76.0) 
Median NAb AUC during the first two years (Years*NU/mL), 
EP3 
1013.5 (1272.1) 1016.5 (1285.4) 
Median maximum NAb titer during the first two years (NU/ml), 
EP4 
102 (112.7) 118 (136.4) 
Minimal maximum NAb titer in any individual (NU/ml)  20 20 
Median time to the presence of a positive NAb titer, if NAbs 
were developed (months), EP5 
6 (0) 6 (0) 
Spearman correlation of mean NAb titer to NAb AUC 0.978 0.985 
Spearman correlation of mean NAb titer to max. NAb titer 0.981 0.984 







Supplementary Table e-5: Summary statistics for the association analysis of NAb AUC with 
candidate markers (linear regression). Significance thresholds and abbreviations are as 
described in the legend of Table 2; SE = standard error. 
Chr. Gene Allele /  
Variant 




6 HLA-DRB1 *04:01 11.9 678 0.41 0.13 >0 1.2×10-­03 6.0×10-­04 
6 HLA-DRB1 *04:08 2.1 678 0.78 0.33 >0 1.7×10-­02 8.6×10-­03 
6 HLA-DRB1 *07:01 9.5 678 0.24 0.07 >0 1.5×10-­03 7.7×10-­04 
6 HLA-DRB1 *15 25.5 678 -0.12 0.05 >0 1.6×10-­02 9.9×10-­01 
6 HLA-DRB1 *15:01 24.0 678 -0.12 0.05 >0 1.5×10-­02 9.9×10-­01 
6 HLA-DRB1 *16:01 2.6 678 0.22 0.19 >0 2.7×10-­01 1.3×10-­01 
6 HLA-DRB1 *03:01 2.9 678 -0.08 0.06 <0 2.3×10-­01 1.1×10-­01 
6 HLA-DRB1 *04:04 0.4 678 -0.12 0.15 <0 4.1×10-­01 2.0×10-­01 
6 HLA-DRB1 *11:01 1.2 678 -0.18 0.08 <0 3.6×10-­02 1.8×10-­02 
6 HLA-DRB1 *11:04 6.9 678 -0.2.0 0.13 <0 1.2×10-­01 5.8×10-­02 
8 intergenic rs4961252_G 40.6 941 -0.07 0.04 >0 9.6×10-­02 9.5×10-­01 
6 intergenic rs9272105_A 49.0 941 -0.08 0.04 <0 2.0×10-­02 9.8×10-­03 
 
Supplementary Table e-6: Summary statistics for the association analysis of maximum NAb 
titer with candidate markers (linear regression). Significance thresholds and abbreviations 
are as described in the legend of Table 2; SE = standard error. 
Chr. Gene Allele /  
Variant 




6 HLA-DRB1 *04:01 11.9 678 0.38 0.13 >0 2.8×10-­03 1.4×10-­03 
6 HLA-DRB1 *04:08 2.1 678 0.74 0.33 >0 2.3×10-­02 1.2×10-­02 
6 HLA-DRB1 *07:01 9.5 678 0.25 0.07 >0 7.3×10-­04 3.7×10-­04 
6 HLA-DRB1 *15 25.5 678 -0.11 0.05 >0 2.4×10-­02 9.9×10-­01 
6 HLA-DRB1 *15:01 24.0 678 -0.12 0.05 >0 1.9×10-­02 9.9×10-­01 
6 HLA-DRB1 *16:01 2.6 678 0.20 0.19 >0 3.0×10-­01 1.5×10-­01 
6 HLA-DRB1 *03:01 2.9 678 -0.08 0.06 <0 2.0×10-­01 1.0×10-­01 
6 HLA-DRB1 *04:04 0.4 678 -0.09 0.15 <0 5.5×10-­01 2.8×10-­01 
6 HLA-DRB1 *11:01 1.2 678 -0.18 0.08 <0 3.1×10-­02 1.6×10-­02 
6 HLA-DRB1 *11:04 6.9 678 -0.20 0.13 <0 1.1×10-­01 5.7×10-­02 
8 intergenic rs4961252_G 40.6 941 -0.07 0.04 >0 7.8×10-­02 9.6×10-­01 





Supplementary Table e-7: Summary statistics for the association analysis of mean NAb titer 
with candidate markers in NAb-positive patients (linear regression). Significance thresholds 
and abbreviations are as described in the legend of Table 2; SE = standard error. 
Chr. Gene Allele / 
Variant 




6 HLA-DRB1 *04:01 11.3 247 0 0.21 >0 9.9×10-­01 5.0×10-­01 
6 HLA-DRB1 *04:08 1.8 247 1.58 0.60 >0 9.4×10-­03 4.7×10-­03 
6 HLA-DRB1 *07:01 11.9 247 0.32 0.14 >0 2.7×10-­02 1.4×10-­02 
6 HLA-DRB1 *15 22.1 247 -0.06 0.11 >0 5.7×10-­01 7.2×10-­01 
6 HLA-DRB1 *15:01 20.6 247 -0.11 0.11 >0 3.3×10-­01 8.4×10-­01 
6 HLA-DRB1 *16:01 1.8 247 0.25 0.43 >0 5.7×10-­01 2.8×10-­01 
6 HLA-DRB1 *03:01 5.1 247 -0.15 0.14 <0 2.8×10-­01 1.4×10-­01 
6 HLA-DRB1 *04:04 0.6 247 0.35 0.36 <0 3.4×10-­01 8.3×10-­01 
6 HLA-DRB1 *11:01 1.4 247 -0.31 0.21 <0 1.5×10-­01 7.3×10-­02 
6 HLA-DRB1 *11:04 5.3 247 -0.21 0.30 <0 4.7×10-­01 2.4×10-­01 
8 intergenic rs4961252_G 38.8 353 -0.16 0.09 >0 6.4×10-­02 9.7×10-­01 
6 intergenic rs9272105_A 46.6 353 -0.16 0.07 <0 2.9×10-­02 1.4×10-­02 
 
Supplementary Table e-8: Summary statistics for the association analysis of NAb AUC with 
candidate markers in NAb-positive patients (linear regression). Significance thresholds and 
abbreviations are as described in the legend of Table 2; SE = standard error. 
Chr. Gene Allele /  
Variant 




6 HLA-DRB1 *04:01 11.3 247 0.07 0.21 >0 7.4×10-­01 3.7×10-­01 
6 HLA-DRB1 *04:08 1.8 247 1.58 0.60 >0 9.3×10-­03 4.6×10-­03 
6 HLA-DRB1 *07:01 11.9 247 0.22 0.15 >0 1.2×10-­01 6.2×10-­02 
6 HLA-DRB1 *15 22.1 247 -0.09 0.11 >0 4.4×10-­01 7.8×10-­01 
6 HLA-DRB1 *15:01 20.6 247 -0.13 0.11 >0 2.4×10-­01 8.8×10-­01 
6 HLA-DRB1 *16:01 1.8 247 0.08 0.44 >0 8.6×10-­01 4.3×10-­01 
6 HLA-DRB1 *03:01 5.1 247 -0.14 0.14 <0 3.1×10-­01 1.5×10-­01 
6 HLA-DRB1 *04:04 0.6 247 0.26 0.36 <0 4.8×10-­01 7.6×10-­01 
6 HLA-DRB1 *11:01 1.4 247 -0.33 0.21 <0 1.2×10-­01 6.0×10-­02 
6 HLA-DRB1 *11:04 5.3 247 -0.23 0.30 <0 4.4×10-­01 2.2×10-­01 
8 intergenic rs4961252_G 38.8 353 -0.17 0.09 >0 4.9×10-­02 9.8×10-­01 





Supplementary Table e-9: Summary statistics for the association analysis of maximum NAb 
titer with candidate markers in NAb-positive patients (linear regression). Significance 
thresholds and abbreviations are as described in the legend of Table 2; SE = standard error. 
Chr. Gene Allele /  
Variant 




6 HLA-DRB1 *04:01 11.3 247 -0.03 0.21 >0 9.0×10-­01 5.5×10-­01 
6 HLA-DRB1 *04:08 1.8 247 1.57 0.60 >0 9.9×10-­03 4.9×10-­03 
6 HLA-DRB1 *07:01 11.9 247 0.33 0.14 >0 2.2×10-­02 1.1×10-­02 
6 HLA-DRB1 *15 22.1 247 -0.03 0.11 >0 7.6×10-­01 6.2×10-­01 
6 HLA-DRB1 *15:01 20.6 247 -0.09 0.11 >0 4.1×10-­01 7.9×10-­01 
6 HLA-DRB1 *16:01 1.8 247 0.05 0.44 >0 9.0×10-­01 4.5×10-­01 
6 HLA-DRB1 *03:01 5.1 247 -0.14 0.14 <0 3.0×10-­01 1.5×10-­01 
6 HLA-DRB1 *04:04 0.6 247 0.43 0.36 <0 2.4×10-­01 8.8×10-­01 
6 HLA-DRB1 *11:01 1.4 247 -0.33 0.21 <0 1.2×10-­01 5.8×10-­02 
6 HLA-DRB1 *11:04 5.3 247 -0.19 0.30 <0 5.3×10-­01 2.6×10-­01 
8 intergenic rs4961252_G 38.8 353 -0.18 0.09 >0 4.3×10-­02 9.8×10-­01 
6 intergenic rs9272105_A 46.6 353 -0.18 0.07 <0 1.6×10-­02 7.8×10-­03 
 
Supplementary Table e-10: Summary statistics for the association analysis of time to first 
NAb presence with candidate markers in NAb-positive patients (Cox proportional hazard 
model). Because of genomic inflation (λ = 1.095), p-values were adjusted using genomic 
control. Significance thresholds and abbreviations are as described in the legend of Table 2; 
SE = standard error. 








6 HLA-DRB1 *04:01 11.3 247/247 0.17 0.21 <0 4.2×10-­01 7.9×10-­01 
6 HLA-DRB1 *04:08 1.8 247/247 1.03 0.59 <0 8.3×10-­02 9.6×10-­01 
6 HLA-DRB1 *07:01 11.9 247/247 -0.11 0.15 <0 4.5×10-­01 2.2×10-­01 
6 HLA-DRB1 *15 22.1 247/247 -0.18 0.10 <0 7.5×10-­02 3.7×10-­02 
6 HLA-DRB1 *15:01 20.6 247/247 -0.15 0.10 <0 1.4×10-­01 6.8×10-­02 
6 HLA-DRB1 *16:01 1.8 247/247 -0.29 0.43 <0 5.0×10-­01 2.5×10-­01 
6 HLA-DRB1 *03:01 5.1 247/247 0.13 0.13 >0 3.3×10-­01 1.6×10-­01 
6 HLA-DRB1 *04:04 0.6 247/247 -0.40 0.36 >0 2.6×10-­01 8.7×10-­01 
6 HLA-DRB1 *11:01 1.4 247/247 -0.11 0.22 >0 6.0×10-­01 7.0×10-­01 
6 HLA-DRB1 *11:04 5.3 247/247 0.12 0.28 >0 6.6×10-­01 3.3×10-­01 
8 intergenic rs4961252_G 38.8 353/353 -0.10 0.09 <0 2.9×10-­01 1.4×10-­01 





Supplementary Table e-11: Summary statistics of genome-wide significant variants for the 
association analysis of EP1-EP4 in all patients. Significance threshold α=5×10-8; 
abbreviations are as described in the legend of Table 2; SE = standard error (EP2-4 are 
quantitative). 
EP Chr. Gene Variant Freq. (%) n OR / Effect CI / SE p-value λ 
EP1 6 intergenic rs522308_T 25.0 941 2.60 2.05-3.29 2.30×10-­15 1.025 
EP2 6 intergenic rs2454138_A 22.0 941 0.41 0.05 5.29×10-­19 1.015 
EP3 6 intergenic rs2454138_A 22.0 941 0.41 0.05 8.44×10-­19 1.015 
EP4 6 intergenic rs2454138_A 22.0 941 0.41 0.05 1.00×10-­18 1.014 
 
 
Supplementary Table e-12: Significant single-tissue eQTLs of variant rs522308 in whole 
blood, GTEx Analysis Release V7. 
SNP Gene Effect p-value 
rs522308 HLA-DQA2 1 2.00×10-­54 
rs522308 HLA-DRB6 0.72 1.10×10-­32 
rs522308 HLA-DQB2 0.62 4.50×10-­21 
rs522308 HLA-DRB1 -0.21 3.30×10-­16 
rs522308 HLA-DQB1 -0.44 5.70×10-­16 
rs522308 HLA-DQA1 -0.23 1.90×10-­11 
rs522308 HLA-DQB1-AS1 -0.24 4.80×10-­07 





Supplementary Figure e-1: Population substructure analysis. The plot shows scaled MDS 
components of the genetic similarity matrix. MDS components were calculated in PLINK2 
v1.90b3.27 using the eigendecomposition-based algorithm. IBS/IBD computation was 
conducted using the command --genome after filtering of genotyped variants (MAF ≥ 0.05, 
HWE p-value ≥ 10-3, removal of the extended MHC region (chromosome 6, 25-35 Mbp) and 
a typical inversion site on chromosome 8 (7-13 Mbp)), and pruning (command --indep-
pairwise 200 100 0.2). Country codes: CA = Canada, GB = Great Britain, SE = Sweden, DE 
= Germany, BE = Belgium, IT = Italy, PL = Poland, UA = Ukraine, FI = Finland, US = United 
States, AU = Australia, DK = Denmark, AT = Austria, FR = France, AR = Argentina, CZ = 
Czech Republic, RU = Russia, IE = Ireland, NO = Norway, NL = Netherlands, CH = 
Switzerland, ES = Spain, LV = Latvia, HU = Hungary, IL = Israel.  












Supplementary Figure e-2: Manhattan plot of GWAS of EP1 in all patients, showing the 
strength of evidence for association with NAb presence. The gray line marks the genome-






Supplementary Figure e-3: Manhattan plot of GWAS of EP2 in all patients, showing the 
strength of evidence for association with mean NAb titer. The gray line marks the genome-






Supplementary Figure e-4: Manhattan plot of GWAS of EP3 in all patients, showing the 
strength of evidence for association with NAb AUC. The gray line marks the genome-wide 





Supplementary Figure e-5: Manhattan plot of GWAS of EP4 in all patients, showing the 
strength of evidence for association with the maximum NAb titer. The gray line marks the 
genome-wide significance level and the red diamond the top SNP rs2454138. Genomic 





Supplementary Figure e-6: Manhattan plot of GWAS of EP2 in NAb-positive patients, 
showing the strength of evidence for association with mean NAb titer. The gray line marks 





Supplementary Figure e-7: Manhattan plot of GWAS of EP3 in NAb-positive patients, 
showing the strength of evidence for association with NAb AUC. The gray line marks the 





Supplementary Figure e-8: Manhattan plot of GWAS of EP4 in NAb-positive patients, 
showing the strength of evidence for association with maximum NAb titer. The gray line 





Supplementary Figure e-9: Manhattan plot of GWAS of EP5 in NAb-positive patients, 
showing the strength of evidence for association with time to first NAb presence. The gray 
line marks the genome-wide significance level. Genomic inflation λ = 0.974. 
 
